This is a preview of subscription content, log in via an institution to check access.
Notes
2013 euros
Reference
Uyl-de Groot CA, et al. Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. Health Economics Review : 17 Jul 2018. Available from: URL: https://doi.org/10.1186/s13561-018-0197-3
Rights and permissions
About this article
Cite this article
Cetuximab not cost effective for metastatic CRC in Netherlands. PharmacoEcon Outcomes News 808, 12 (2018). https://doi.org/10.1007/s40274-018-5127-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5127-4